GCG and metabolic dysfunction-associated steatohepatitis: Interventions for DM such as pioglitazone, glucagon like peptide-1 (GLP-1), and sodium‐glucose cotransporter 2 inhibitor (SGLT2I) have been reported to provide benefits in nonalcoholic steatohepatitis[15–17].